Article info
PDFHelicobacter pylori
Original research
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
- Correspondence to Dr Dominique Velin, Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland; dominique.velin{at}chuv.ch
Citation
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Publication history
- Received October 17, 2020
- Accepted June 24, 2021
- First published July 12, 2021.
Online issue publication
February 08, 2022
Article Versions
- Previous version (12 July 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.